Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an Australia-based, oncology-focused drug development company, announced on Friday that it has received Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) for the company's paxalisib to treat atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly-aggressive childhood brain cancer.
ODD provides drug developers with up to seven years of Orphan Drug Exclusivity (ODE), during which competitors are not able to rely on the company's data to produce generic versions of paxalisib, effectively extending the effective life of a commercial product. It also offers opportunities for grant funding and protocol assistance, and tax credits.
The FDA is waiving fees regarding a future regulatory filing in AT/RT, potentially saving over USD3m if the company seeks approval in this indication.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling